

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Search Results -

Term	Documents
B7-2.USPT,PGPB.	172
B7-2S	0
ANTIBOD\$	0
ANTIBOD.USPT,PGPB.	241
ANTIBODAY.USPT,PGPB.	1
ANTIBODEES.USPT,PGPB.	1
ANTIBODEIS.USPT,PGPB.	1
ANTIBODES.USPT,PGPB.	48
ANTIBODES:.USPT,PGPB.	1
ANTIBODEY.USPT,PGPB.	1

TREAT\$(TREATMENT/POST).CLM.	pickup term
((B7-2) SAME (ANTIBOD\$ OR IMMUNOGLOBULIN\$) SAME (INHIBIT\$ OR SUPPRESS\$ OR BLOCK\$ OR TREAT\$ OR THERAP\$ OR PREVENT\$) .CLM.).USPT,PGPB.	1

There are more results than shown above. [Click here to view the entire set.](#)

Database:

☐ US Patents Full-Text Database
☐ US Pre-Grant Publication Full-Text Database
☐ JPO Abstracts Database
☐ EPO Abstracts Database
☐ Derwent World Patents Index
☐ IBM Technical Disclosure Bulletins

Refine Search:

('b7-2') same (antibod\$ or
 immunoglobulin\$) same (inhibit\$ or
 suppress\$ or block\$ or treat\$ or therap\$

[Clear](#)**Search History**

Today's Date: 8/19/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB	('b7-2') same (antibod\$ or immunoglobulin\$) same (inhibit\$ or suppress\$ or block\$ or treat\$ or therap\$ or prevent\$) .clm.	1	<u>L2</u>
USPT,PGPB	('b7-2') same (antibod\$ or immunoglobulin\$) same (inhibit\$ or suppress\$ or block\$ or treat\$ or therap\$ or prevent\$)	58	<u>L1</u>

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms

Search Results -

Term	Documents
B7-2.USPT,PGPB.	172
B7-2S	0
ANTIBOD\$	0
ANTIBOD.USPT,PGPB.	241
ANTIBODAY.USPT,PGPB.	1
ANTIBODEES.USPT,PGPB.	1
ANTIBODEIS.USPT,PGPB.	1
ANTIBODES.USPT,PGPB.	48
ANTIBODES:.USPT,PGPB.	1
ANTIBODEY.USPT,PGPB.	1
.....	
TREAT\$(TREATMENT/POST).USPT,PGPB.	pickup term
((('B7-2') SAME (ANTIBOD\$ OR IMMUNOGLOBULIN\$) SAME (INHIBIT\$ OR SUPPRESS\$ OR BLOCK\$ OR TREAT\$ OR THERAP\$ OR PREVENT\$)).USPT,PGPB.	58

[There are more results than shown above. Click here to view the entire set.](#)

Database:

☐ US Patents Full-Text Database
☐ US Pre-Grant Publication Full-Text Database
☐ JPO Abstracts Database
☐ EPO Abstracts Database
☐ Derwent World Patents Index
☐ IBM Technical Disclosure Bulletins

Refine Search:

('b7-2') same (antibod\$ or
 immunoglobulin\$) same (inhibit\$ or
 suppress\$ or block\$ or treat\$ or therap\$

[Clear](#)**Search History**

Today's Date: 8/19/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB	('b7-2') same (antibod\$ or immunoglobulin\$) same (inhibit\$ or suppress\$ or block\$ or treat\$ or therap\$ or prevent\$)	58	<u>L1</u>

--Important Notice to Freelance Author--
See HELP FREELANCE for more information

NEW FILE RELEASED

***EIU Bine Magaine (File 622)
***IBISWorld Market Research (File 753)
***Inetext PDF Index (File 745)
***Dail and Snda Telegraph (London) Paper (File 756)
***The Mirror Grop Pblication (United Kingdom) (File 757)

UPDATING RESUMED

***Delphe Eropean Bine (File 481)
***Book In Print (File 470)

RELOADED

***Kompa Middle Eat/Africa/Mediterranean (File 585)
***Kompa Aia/Pacific (File 592)
***Kompa Central/Eatern Erope (File 593)
***Kompa Canada (File 594)
***CANCERLIT (File 159)
***Information Science Abtract (File 202)

New docment pplier

IMED ha been changed to INFOTRIE (ee HELP OINFOTRI)

>>>Get immediate new with Dialog' Firt Releae
new erice. Firt Releae pdate major newwire
databae within 15 minte of tranmilion oer the
wire. Firt Releae proide fll Dialog earchabilit
and fll-text featre. To earch Firt Releae file in
OneSearch impl BEGIN FIRST for coerage from Dialog'
broad pectrm of new wire.

>>> Enter BEGIN HOMEBASE for Dialog Annoncement <<<
>>> of new databae, price change, etc. <<<

* * *

* * *

File 1:ERIC 1966-2001/Ag 17
(c) format onl 2001 The Dialog Corporation

Set	Item	Decription
---	-----	-----

? □dialog

>>>'IALOG' not recognized as set or accession number
? b 410

19aug01 07:27:38 User208760 Session D1908.1
\$0.45 0.130 DialUnits File1
\$0.45 Estimated cost File1
\$0.05 TYMNET
\$0.50 Estimated cost this search
\$0.50 Estimated total session cost 0.130 DialUnits

File 410:Chronolog(R) 1981-2001/July

```
Set  Items  Description
---  -
? set hi ;set hi

HILIGHT set on as ''
HILIGHT set on as ''
? begin 5,73,155,399

19aug01 07:27:43 User208760 Session D1908.2
$0.00      0.059 DialUnits File410
$0.00 Estimated cost File410
$0.00 Estimated cost this search
$0.50 Estimated total session cost  0.188 DialUnits
```

```
SYSTEM:OS - DIALOG OneSearch
File 5:Biosis Previews(R) 1969-2001/Aug W2
(c) 2001 BIOSIS
File 73:EMBASE 1974-2001/Aug W2
(c) 2001 Elsevier Science B.V.
*File 73: For information about Explode feature please
see Help News73.
File 155:MEDLINE(R) 1966-2001/Sep W2
File 399:CA SEARCH(R) 1967-2001/UD=13508
(c) 2001 AMERICAN CHEMICAL SOCIETY
*File 399: Use is subject to the terms of your user/customer agreement.
RANK charge added; see HELP RATES 399.
```

```
Set  Items  Description
---  -
? s (b7-2)

S1      232 (B7-2)
? rd s1

...examined 50 records (50)
...examined 50 records (100)
...examined 50 records (150)
...examined 50 records (200)
...completed examining records
S2      229 RD S1 (unique items)
? s s2 and py=1990\
```

```
229 S2
0 PY=1990\
S3      0 S2 AND PY=1990\
? s s2 and py=1990
```

```
229 S2
1840939 PY=1990
S4      0 S2 AND PY=1990
? s s2 and py=1991
```

```
229 S2
1825836 PY=1991
S5      0 S2 AND PY=1991
? s s2 and py=1992
```

```
229 S2
1827727 PY=1992
S6      0 S2 AND PY=1992
? s s2 and py=1993
```

```
229 S2
```

1865607 PY=1993
S7 0 S2 AND PY=1993
? s s2 and py=1994

229 S2
1919766 PY=1994
S8 1 S2 AND PY=1994
? t s8/7/all

8/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09661780 BIOSIS NO.: 199598116698
Immunoglobulin fold characteristics of B7-1 (CD80) and B7-2 (CD86).
AUTHOR: Bajorath Jurgen(a); Peach Robert J; Linsley Peter S
AUTHOR ADDRESS: (a)Bristol-Myers Squibb Pharmaceutical Res. Inst., 3005
First Avenue, Seattle, WA 98121**USA
JOURNAL: Protein Science 3 (11):p2148-2150 1994
ISSN: 0961-8368
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: B7-1 and B7-2 are expressed on antigen-presenting cells and bind to the CD28 and CTLA-4 receptors on T cells . These interactions trigger a costimulatory pathway that is essential for T-cell activation. B7-1 and B7-2 are members of the immunoglobulin superfamily (IgSF) and, despite sharing common function, have only limited sequence similarity. The B7-1 extracellular region was previously subdivided into 2 IgSF domains, an N-terminal V(aria)le-like domain, followed by a C(onstant)like domain. We recently reported that the V-like domains of B7-1 and B7-2 share some significant sequence similarities with 3 major histocompatibility complex (MHC)-encoded members of the IgSF. We have now applied inverse folding methodology to assess the compatibility of the B7-1 and B7-2 extracellular region sequences with currently available 3-dimensional structures. In these calculations, the sequences of the N-terminal (V-like) domains in B7-1 and B7-2 were not compatible with known structures, including the IgSF V-set. In contrast, the sequences of the C-like domains were compatible with IgSF C-set structures and were best recognized by the beta-2-microglobulin (beta-2m) domain of MHC Class I. A sequence comparison of the C-like domains in the B7 molecules showed that 11 of 17 rigorously conserved residues in B7-1 and B7-2 are not IgSF C-1 set consensus residues. When mapped onto the corresponding positions of the beta-2m structure, the conserved residues in B7 cluster on the surface, where they may interact with the B7 V-like domain or other molecules.

? s s2 and review?

229 S2
2973527 REVIEW?
S9 0 S2 AND REVIEW?
? ds

Set	Items	Description
S1	232	(B7-2)
S2	229	RD S1 (unique items)
S3	0	S2 AND PY=1990\
S4	0	S2 AND PY=1990
S5	0	S2 AND PY=1991
S6	0	S2 AND PY=1992
S7	0	S2 AND PY=1993
S8	1	S2 AND PY=1994

S9 0 S2 AND REVIEW?

? s s2 and review?

229 S2

2973527 REVIEW?

S10 0 S2 AND REVIEW?

? e au=freeman gordon ?

Ref	Items	Index-term
E1	14	AU=FREEMAN GM
E2	7	AU=FREEMAN GORDON
E3	0	*AU=FREEMAN GORDON ?
E4	73	AU=FREEMAN GORDON J
E5	5	AU=FREEMAN GR
E6	2	AU=FREEMAN GRAHAM H
E7	1	AU=FREEMAN GREGORY
E8	1	AU=FREEMAN GREGORY A
E9	73	AU=FREEMAN GREGORY L
E10	1	AU=FREEMAN GREGORY LANE
E11	1	AU=FREEMAN GREOGRY L
E12	1	AU=FREEMAN GRUNES W.

Enter P or PAGE for more.

? s e4

S11 73 AU="FREEMAN GORDON J"

? s s11 and b7?

73 S11

18366 B7?

S12 47 S11 AND B7?

? rd si2

...completed examining records

S13 45 RD S12 (unique items)

? s s13 and py=1990

45 S13

1840939 PY=1990

S14 0 S13 AND PY=1990

? s s13 and py=1991

45 S13

1825836 PY=1991

S15 0 S13 AND PY=1991

? s s13 and py=1992

45 S13

1827727 PY=1992

S16 2 S13 AND PY=1992

? s s13 and py=1993

45 S13

1865607 PY=1993

S17 9 S13 AND PY=1993

? s s2 and py=1993

229 S2

1865607 PY=1993

S18 0 S2 AND PY=1993

? t s s13 and py=1994

>>>'13' valid only in keyword format

? s s13 and py=1994

45 S13
1919766 PY=1994
S19 6 S13 AND PY=1994
? t s16/3/all

16/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

08757366 BIOSIS NO.: 199395046717
Murine **B7** antigen provides a sufficient costimulatory signal for
antigen-specific and MHC-restricted T cell activation.
AUTHOR: Galvin Frances; **Freeman Gordon J**; Razi-Wolf Ziba; Hall
William Jr; Benacerraf Baruji; Nadler Lee; Reiser Hans(a
AUTHOR ADDRESS: (a)Div. Lymphocyte Biol., Dana-Farber Cancer Inst., 44
Binney St., Boston, Mass. 02115
JOURNAL: Journal of Immunology 149 (12):p3802-3808 **1992**
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

16/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

08757365 BIOSIS NO.: 199395046716
CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation:
Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of
lymphokine production.
AUTHOR: **Freeman Gordon J**(a); Lombard David B; Gimmi Claude D; Brod
Staley A; Lee Kelvin; Laning Joseph C; Hafler David A; Dorf Martin E;
Gray Gary S; et al
AUTHOR ADDRESS: (a)Div. Tumor Immunology, Dana-Farber Cancer Inst., Mayer
726, 44 Binney St., Boston, Mass. 02115
JOURNAL: Journal of Immunology 149 (12):p3795-3801 **1992**
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
? t s17/3/all

17/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09066685 BIOSIS NO.: 199497075055
Murine **B7-2**, an alternative CTLA4 counter-receptor that costimulates
T cell proliferation and interleukin 2 production.
AUTHOR: **Freeman Gordon J**(a); Borriello Frank; Hodes Richard J; Reiser
Hans; Griben John G; Ng Judy W; Kim Jinny; Goldberg John M; Hathcock
Karen; et al
AUTHOR ADDRESS: (a)Div. Hematol. Malignancies, Dana-Farber Cancer Inst., 44
Binney St., Boston, MA 02115**USA
JOURNAL: Journal of Experimental Medicine 178 (6):p2185-2192 **1993**
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

17/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09061095 BIOSIS NO.: 199497069465
Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.
AUTHOR: Boussiotis Vassiliki A(a); **Freeman Gordon J**; Gribben John G; Daley John; Gray Gary; Nadler Lee M
AUTHOR ADDRESS: (a)Div. Hematologic Malignancies, Dana-Farber Cancer Inst., Dep. Med., Harvard Med. Sch., Boston, M**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 90 (23):p11059-11063 1993
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

17/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09037508 BIOSIS NO.: 199497045878
B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance.
AUTHOR: Boussiotis Vassiliki A(a); **Freeman Gordon J**; Gray Gary; Gribben John; Nadler Lee M
AUTHOR ADDRESS: (a)Dana Farber Cancer Inst., Mayer 730, 44 Binney Street, Boston, MA 02115**USA
JOURNAL: Journal of Experimental Medicine 178 (5):p1753-1763 1993
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

17/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09033626 BIOSIS NO.: 199497041996
Uncovering of functional alternative CTLA-4 counter-receptor in **B7**-deficient mice.
AUTHOR: **Freeman Gordon J**; Borriello Frank; Hodes Richard J; Reiser Hans; Hathcock Karen S; Laszlo Gloria; McKnight Andrew J; Kim Jinny; Du Lina; Lombard David B; Gray Gary S; Nadler Lee M; Sharpe Arlene H(a)
AUTHOR ADDRESS: (a)Immunology Res. Div., Dep. Pathology, Brigham Women's Hosp., Harvard Med. Sch., Boston, MA 02115**USA
JOURNAL: Science (Washington D C) 262 (5135):p907-909 1993
ISSN: 0036-8075
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

17/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09033625 BIOSIS NO.: 199497041995
Cloning of **B7-2**: A CTLA-4 counter-receptor that costimulates human T cell proliferation.
AUTHOR: **Freeman Gordon J**(a); Gribben John G; Boussiotis Vassiliki A; Ng Judy W; Restivo Vincent A Jr; Lombard Lisa A; Gray Gary S; Nadler Lee

M

AUTHOR ADDRESS: (a)Div. Hematologic Malignancies, Dana-Farber Cancer Inst.,
Boston, MA 02115**USA
JOURNAL: Science (Washington D C) 262 (5135):p909-911 1993
ISSN: 0036-8075
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

17/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

08981057 BIOSIS NO.: 199396132558
Characterization of CTLA-4 structure and expression on human T cells.
AUTHOR: Lindsten Tullia; Lee Kelvin P; Harris Estelle S; Petryniak
Bronislawa; Craighead Nancy; Reynolds Pamela J; Lombard David B;
Freeman Gordon J; Nadler Lee M; et al
AUTHOR ADDRESS: Inq: Carl H. June, Tissue Bank, Mail Stop 44, Dep.
Immunobiol., Naval Med. Res. Inst., Bethesda, MD **USA
JOURNAL: Journal of Immunology 151 (7):p3489-3499 1993
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

17/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

08920828 BIOSIS NO.: 199396072329
Human T-cell clonal anergy is induced by antigen presentation in the
absence of **B7** costimulation.
AUTHOR: Gimmi Claude D(a); **Freeman Gordon J**(a); Gribben John G(a);
Gray Gary; Nadler Lee M(a)
AUTHOR ADDRESS: (a)Div. Tumor Immunol., Dana-Farber Cancer Inst., Harvard
Med. Sch., Boston, MA 02115**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United
States of America 90 (14):p6586-6590 1993
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

17/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

08902107 BIOSIS NO.: 199396053608
Constitutive expression of **B7** restores immunogenicity of tumor cells
expressing truncated major histocompatibility complex class II molecules.
AUTHOR: Baskar Sivasubramanian; Ostrand-Rosenberg Suzanne(a); Nabavi Nasrin
; Nadler Lee M; **Freeman Gordon J**; Glimcher Laurie H
AUTHOR ADDRESS: (a)Dep. Biological Sci., Univ. Maryland, Baltimore, MD
21228**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United
States of America 90 (12):p5687-5690 1993
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

17/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

08788769 BIOSIS NO.: 199395078120
Effects of cyclosporin A, FK 506, and mycalamide A on the activation of
murine CD4-positive T cells by the murine **B7** antigen.
AUTHOR: Galvin Frances; **Freeman Gordon J**; Razi-Wolf Ziba; Benacerraf
Baruj; Nadler Lee; Reiser Hans(a
AUTHOR ADDRESS: (a)Div. Lymphocyte Biology, Dana-Farber Cancer Inst., 44
Binney Street, Boston, Mass. 02115
JOURNAL: European Journal of Immunology 23 (1):p283-286 1993
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
? ds

Set	Items	Description
S1	232	(B7-2)
S2	229	RD S1 (unique items)
S3	0	S2 AND PY=1990\
S4	0	S2 AND PY=1990
S5	0	S2 AND PY=1991
S6	0	S2 AND PY=1992
S7	0	S2 AND PY=1993
S8	1	S2 AND PY=1994
S9	0	S2 AND REVIEW?
S10	0	S2 AND REVIEW?
S11	73	AU="FREEMAN GORDON J"
S12	47	S11 AND B7?
S13	45	RD S12 (unique items)
S14	0	S13 AND PY=1990
S15	0	S13 AND PY=1991
S16	2	S13 AND PY=1992
S17	9	S13 AND PY=1993
S18	0	S2 AND PY=1993
S19	6	S13 AND PY=1994

? t s19/3/all

19/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09594662 BIOSIS NO.: 199598049580
Characterization of the murine **B7-1** genomic locus reveals an
additional exon encoding an alternative cytoplasmic domain and a
chromosomal location of chromosome 16, band B5.
AUTHOR: Borriello Frank; **Freeman Gordon J**; Edelhoff Susanne; Disteché
Christine M; Nadler Lee M; Sharpe Arlene H(a
AUTHOR ADDRESS: (a)Immunol. Res. Div., Dep. Pathol., Brigham and Women's
Hosp., Longwood Med. Res. Cent., 221 Longw**USA
JOURNAL: Journal of Immunology 153 (11):p5038-5048 1994
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

19/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09580861 BIOSIS NO.: 199598035779
Pivotal role of the **B7**:CD28 pathway in transplantation tolerance and tumor immunity.
AUTHOR: Guinan Eva C(a); Gribben John G; Boussiotis Vicki A; **Freeman Gordon J**; Nadler Lee M
AUTHOR ADDRESS: (a)Dep. Pediatric Oncol., Dana-Farber Cancer Inst., 44 Binney St., Boston, MA 02115**USA
JOURNAL: Blood 84 (10):p3261-3282 1994
ISSN: 0006-4971
DOCUMENT TYPE: Literature Review
RECORD TYPE: Citation
LANGUAGE: English

19/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09580658 BIOSIS NO.: 199598035576
CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy.
AUTHOR: Boussiotis Vassiliki A(a); **Freeman Gordon J**; Griffin James D; Gray Gary S; Gribben John G; Nadler Lee M
AUTHOR ADDRESS: (a)Dana-Farber Cancer Inst., Dana 740, 44 Binney St., Boston, MA 02115**USA
JOURNAL: Journal of Experimental Medicine 180 (5):p1665-1673 1994
ISSN: 0022-1007
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

19/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09454960 BIOSIS NO.: 199497463330
The **B7**-2 (**B70**) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen.
AUTHOR: Engel Pablo; Gribben John G; **Freeman Gordon J**; Zhou Liang-Ji; Nozawa Yoshihiro; Abe Masafumi; Nadler Lee M; Wakasa Haruki; Tedder Thomas F(a)
AUTHOR ADDRESS: (a)Dep. Immunology, Box 3010, Duke Univ. Med. Center, Durham, NC 27710**USA
JOURNAL: Blood 84 (5):p1402-1407 1994
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

19/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09261806 BIOSIS NO.: 199497270176
Mice expressing both **B7**-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness.
AUTHOR: Harlan David M(a); Hengartner Hans; Huang Mark L; Kang Yuan-Hsu; Abe Ryo; Moreadith Randall W; Pircher Hanspeter; Gray Gary S; Ohashi Pamela S; **Freeman Gordon J**; Nadler Lee M; June Carl H; Aichele Peter
AUTHOR ADDRESS: (a)Immunobiol. Dep., Naval Med. Res. Inst., Bethesda, MD

20889**USA
JOURNAL: Proceedings of the National Academy of Sciences of the United
States of America 91 (8):p3137-3141 **1994**
ISSN: 0027-8424
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

19/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09153797 BIOSIS NO.: 199497162167
A family of **B7** molecules costimulates T cell proliferation.
AUTHOR: **Freeman Gordon J**(a); Bousiotis Vassiliki(a); Gray Gary;
Gribben John G(a); Nadler Lee M(a)
AUTHOR ADDRESS: (a)Dana-Farber Cancer Inst., Boston, MA 02115**USA
JOURNAL: Journal of Cellular Biochemistry Supplement 0 (18B):p50
1994
CONFERENCE/MEETING: Keystone Symposium on Advances and Controversies in
Bone Marrow Transplantation Keystone, Colorado, USA January 23-30, 1994
ISSN: 0733-1959
RECORD TYPE: Citation
LANGUAGE: English

SYSTEM:OS - DIALOG OneSearch

File 652:US Patents Fulltext 1971-1979

(c) format only 2001 The Dialog Corp.

*File 652: Reassignment data current through June 6, 2001 recordings.
Due to processing problems, the SORT command is not working.

File 653:US Patents Fulltext 1980-1989

(c) format only 2001 The Dialog Corp.

*File 653: Reassignment data current through June 6, 2001 recordings.
Due to processing problems, the SORT command is not working.

File 654:US PAT.FULL. 1990-2001/AUG 13

(c) format only 2001 The Dialog Corp.

*File 654: Reassignment data current through June 6, 2001 recordings

Set	Items	Description
---	-----	-----
? s (b7-2)		
S1	0	(B7-2)
? s (b7(w)2)		
Processing		
Processing		
Processing		
Processing		
	7662	B7
	3067312	2
S2	339	(B7(W)2)
? s (b7(w)2) (20n) (antibod? or immunoglobulin?) (20n) (inhibit? or treat? or therap? or administ? or prevent? or suppress? or block?)		
Processing		
Processing		
Processing		
Processing		
Processing		
Processing		
	7662	B7
	3067312	2
	50574	ANTIBOD?
	16849	IMMUNOGLOBULIN?
	326794	INHIBIT?
	693697	TREAT?
	118487	THERAP?
	172662	ADMINIST?
	1424547	PREVENT?
	169433	SUPPRESS?
	944364	BLOCK?
S3	70	(B7(W)2) (20N) (ANTIBOD? OR IMMUNOGLOBULIN?) (20N) (INHIBIT? OR TREAT? OR THERAP? OR ADMINIST? OR PREVENT? OR SUPPRESS? OR BLOCK?)
? t s3/3/all		

3/3/1 (Item 1 from file: 654)

DIALOG(R) File 654:US PAT.FULL.

(c) format only 2001 The Dialog Corp. All rts. reserv.

03354414

Utility
TETRACYCLINE-INDUCIBLE TRANSCRIPTIONAL INHIBITOR FUSION PROTEINS

PATENT NO.: 6,271,348
ISSUED: August 07, 2001 (20010807)
INVENTOR(s): Bujard, Hermann, Heidelberg, DE (Germany)
Gossen, Manfred, El Cerrito, CA (California), US (United States of America)
ASSIGNEE(s): BASF Aktiengesellschaft, (A Non-U.S. Company or Corporation),
Ludwigshafen, DE (Germany)
Knoll Aktiengesellschaft, (A Non-U.S. Company or Corporation),
Ludwigshafen, DE (Germany)
[Assignee Code(s): 4911; 7016]
APPL. NO.: 9-489,777
FILED: January 24, 2000 (20000124)

RELATED APPLICATIONS

This application is a divisional of U.S. Ser. No. 09-162,184, filed Sep. 28, 1998, U.S. Pat. No. 6,136,954, which is a continuation of U.S. Ser. No. 08-485,978, filed Jun. 7, 1995, now U.S. Pat. No. 5,814,618, which is a continuation-in-part of U.S. Ser. No. 08-383,754, filed Feb. 3, 1995, now U.S. Pat. No. 5,789,156, which is a continuation-in-part of U.S. Ser. No. 08-275,876, filed Jul. 15, 1994, now U.S. Pat. No. 5,654,168, which is a continuation-in-part of U.S. Ser. No. 08-270,637, filed Jul. 1, 1994, now abandoned. U.S. Ser. No. 08-485,978 is also a continuation-in-part of U.S. Ser. No. 08-260,452, filed Jun. 14, 1994, now U.S. Pat. No. 5,650,298, which is a continuation-in-part of U.S. Ser. No. 08-076,327, filed Jun. 14, 1993, now abandoned. U.S. Ser. No. 08-485,978 is also a continuation-in-part of Ser. No. 08-076,726, filed Jun. 14, 1993, now U.S. Pat. No. 5,464,758. The entire contents of each of these applications are incorporated herein by reference.

This application claims priority under 35 U.S.C. section 120 to U.S. Ser. No. 09-162,184, filed Sep. 28, 1998, pending, U.S. Ser. No. 08-485,978, filed Jun. 7, 1995, now U.S. Pat. No. 5,814,618, and to U.S. Ser. No. 08-383,754, filed Feb. 3, 1995, now U.S. Pat. No. 5,789,156.

3/3/65 (Item 65 from file: 654)
DIALOG(R) File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02778834

Utility

METHODS AND MATERIALS FOR THE INDUCTION OF T CELL ANERGY

PATENT NO.: 5,747,034
ISSUED: May 05, 1998 (19980505)
INVENTOR(s): de Boer, Mark, Beverwijk, NL (Netherlands)
Conroy, Leah B., Pacifica, CA (California), US (United States
of America)
ASSIGNEE(s): Chiron Corporation, (A U.S. Company or Corporation),
Emeryville, CA (California), US (United States of America)
[Assignee Code(s): 11661]
APPL. NO.: 8-200,716
FILED: February 18, 1994 (19940218)

This application is a continuation-in-part of U.S. application Ser. No.
08-015,147, filed Feb. 3, 1993, now pending, which is a
continuation-in-part of U.S. application Ser. No. 07-910,222, filed Jul. 9,
1992, U.S. Pat. No. 5,397,703.

3/3/60 (Item 60 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02846287

Utility

BLOCKADE OF T LYMPHOCYTE DOWN-REGULATION ASSOCIATED WITH CTLA-4 SIGNALING
[Decreasing growth of tumor cells by administering blocking agent which binds to extracellular domain of cytotoxic T-lymphocyte-associated molecule and inhibits signaling]

PATENT NO.: 5,811,097
ISSUED: September 22, 1998 (19980922)
INVENTOR(s): Allison, James Patrick, Berkeley, CA (California), US (United States of America)
Leach, Dana R., Albany, CA (California), US (United States of America)
Krummel, Matthew F., Berkeley, CA (California), US (United States of America)
ASSIGNEE(s): The Regents of the University of California, (A U.S. Company or Corporation), Oakland, CA (California), US (United States of America)
[Assignee Code(s): 13234]
APPL. NO.: 8-646,605
FILED: May 08, 1996 (19960508)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent application Ser. No. 08-566,853, filed Dec. 4, 1995, which is a continuation-in-part of U.S. patent application Ser. No. 08-506,666, filed Jul. 25, 1995 now

3/3/52 (Item 52 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02901431

Utility

TUMOR CELLS MODIFIED TO EXPRESS B7-2 WITH INCREASED IMMUNOGENICITY AND USES THEREFOR

[Isolated mammalian tumor cell transfected with an exogenous nucleic acid molecule encoding a mammalian B7-2 molecule]

PATENT NO.: 5,861,310

ISSUED: January 19, 1999 (19990119)

INVENTOR(s): Freeman, Gordon J., Brookline, MA (Massachusetts), US (United States of America)

Nadler, Lee M., Newton, MA (Massachusetts), US (United States of America)

Gray, Gary S., Brookline, MA (Massachusetts), US (United States of America)

ASSIGNEE(s): Dana-Farber Cancer Institute, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 11804]

EXTRA INFO: Assignment transaction [Reassigned], recorded May 24, 1999 (19990524)

APPL. NO.: 8-456,104

FILED: May 30, 1995 (19950530)

RELATED APPLICATIONS

This application is a Continuation-in-part of U.S. Ser. No. 08-147,773 filed Nov. 3, 1993 entitled "Tumor Cells Modified to Express B7-2 and B7-3 with Increased Immunogenicity and Uses Therefor"now abandoned. The contents of this application is incorporated herein by reference.

3/3/50 (Item 50 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02910164

Utility

METHODS OF BLOCKING T-CELL ACTIVATION USING ANTI-B7 MONOCLONAL ANTIBODIES
[Administering to patient antibody against B7 antigen and immunosuppressive agent in synergistic mixture; treatment of transplant rejection, graft versus host disease, rheumatoid arthritis]

PATENT NO.: 5,869,050
ISSUED: February 09, 1999 (19990209)
INVENTOR(s): de Boer, Mark, Almere, NL (Netherlands)
Conroy, Leah B., Pacifica, CA (California), US (United States of America)
ASSIGNEE(s): Chiron Corporation, (A U.S. Company or Corporation),
Emeryville, CA (California), US (United States of America)
[Assignee Code(s): 11661]
APPL. NO.: 8-15,147
FILED: February 09, 1993 (19930209)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Ser. No. 07-910,222, filed Jul. 9, 1992, now U.S. Pat. No. 5,397,703, the disclosure of which is hereby incorporated by reference.

3/3/46 (Item 46 from file: 654)
DIALOG(R)File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02991195

Utility

B7-2: A CTLA4/CD28 LIGAND

[A nucleic acid molecule which codes a B lymphocyte activation antigen that stimulates T-cell activation; treatment of autoimmune diseases and transplant rejections]

PATENT NO.: 5,942,607

ISSUED: August 24, 1999 (19990824)

INVENTOR(s): Freeman, Gordon J., Brookline, MA (Massachusetts), US (United States of America)

Nadler, Lee M., Newton, MA (Massachusetts), US (United States of America)

Gray, Gary S., Brookline, MA (Massachusetts), US (United States of America)

ASSIGNEE(s): Dana-Farber Cancer Institute, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)

[Assignee Code(s): 11804]

APPL. NO.: 8-101,624

FILED: July 26, 1993 (19930726)

GOVERNMENT FUNDING

This invention was made with government support under CA-40216-08 awarded by the National Institutes of Health. The U.S. government therefore has certain rights in this invention.

3/3/24 (Item 24 from file: 654)
DIALOG(R) File 654:US PAT.FULL.
(c) format only 2001 The Dialog Corp. All rts. reserv.

03110269

Utility

BLOCKADE OF T LYMPHOCYTE DOWN-REGULATION ASSOCIATED WITH CTLA-4 SIGNALING
[Administering mammalian host an immune response stimulating agent and
CTLA-4(T cell surface molecule) blocking agent to inhibit growth of non-T
cell tumor cells]

PATENT NO.: 6,051,227

ISSUED: April 18, 2000 (20000418)

INVENTOR(s): Allison, James Patrick, Berkeley, CA (California), US (United
States of America)

Leach, Dana R., Albany, CA (California), US (United States of
America)

Krummel, Matthew F., Berkeley, CA (California), US (United
States of America)

ASSIGNEE(s): The Regents of the University of California, Office of
Technology Transfer, (A U.S. Company or Corporation), Oakland,
CA (California), US (United States of America)
[Assignee Code(s): 13234]

APPL. NO.: 8-760,288

FILED: December 04, 1996 (19961204)

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Ser. No. 08-646,605,
filed May 8, 1996, now U.S. Pat. No. 5,811,097, which is a

03147788

Utility

CTLA4/CD28 LIGANDS AND USES THEREFOR

PATENT NO.: 6,084,067

ISSUED: July 04, 2000 (20000704)

INVENTOR(s): Freeman, Gordon J., Brookline, MA (Massachusetts), US (United States of America)
Nadler, Lee M., Newton, MA (Massachusetts), US (United States of America)
Gray, Gary S., Brookline, MA (Massachusetts), US (United States of America)

ASSIGNEE(s): Dana-Farber Cancer Institute, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
Genetics Institute, Inc , (A U.S. Company or Corporation), Cambridge, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 11804; 12457]

APPL. NO.: 8-479,744

FILED: June 07, 1995 (19950607)

PRIORITY: PCT-US94-08423, WO (World Intellectual Property Org), July 26, 1994 (19940726)

RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Ser. No. 08-280,757, entitled "Novel CTLA4-CD28 Ligands and Uses Therefor" filed Jul. 26, 1994, which is a continuation-in-part of U.S. Ser. No. 08-109,393, entitled "Novel CTLA4-CD28 Ligands and Uses Therefor" filed Aug. 19, 1993, now abandoned, which is a continuation-in-part of U.S. Ser. No. 08-101,624, also entitled "Novel CTLA4-CD28 Ligands and Uses Therefor", filed Jul. 26, 1993. This application is also a continuation-in-part of U.S. Ser. No. 08-147,773, entitled "Tumor Cells Modified To Express B7-2 And B7-3 With Increased Immunogenicity And Uses Therefor" filed Nov. 3, 1993 now abandoned. The contents of each of these applications is incorporated

ity

FUSION PROTEINS OF NOVEL CTLA4/CD28 LIGANDS AND USES THEREFORE

PATENT NO.: 6,130,316
ISSUED: October 10, 2000 (20001010)
INVENTOR(s): Freeman, Gordon J., Brookline, MA (Massachusetts), US (United States of America)
Nadler, Lee M., Newton, MA (Massachusetts), US (United States of America)
Gray, Gary S., Brookline, MA (Massachusetts), US (United States of America)
Greenfield, Edward, Randolph, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): Dana Farber Cancer Institute, (A U.S. Company or Corporation), Boston, MA (Massachusetts), US (United States of America)
Repligen Corporation, (A U.S. Company or Corporation), Cambridge, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 11804]
APPL. NO.: 8-280,757
FILED: July 26, 1994 (19940726)

RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Ser. No. 08-109,393, entitled "Novel CTLA4-CD28 Ligands and Uses Therefor" filed Aug. 19, 1993 (abandoned), which is a continuation-in-part of U.S. Ser. No. 08-101,624, also entitled "Novel CTLA4-CD28 Ligands and Uses Therefor", filed Jul. 26, 1993 (abandoned). This application is also a continuation-in-part of U.S. Ser. No. 08-147,773, entitled "Tumor Cells Modified To Express B7-2 And B7-3 With Increased Immunogenicity And Uses Therefor" filed Nov. 3, 1993 (abandoned). The contents of each of these applications is incorporated herein by reference.